TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06307249

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: SNP
Description: Diagnostics of patients' carriers or not of the risk allele(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125mg/day/os over 21 days every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125mg/day/os over 21 days every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125mg/day/os over 21 days every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Palbociclib 125mg/day/os over 21 days every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg every 21 days
Study: NCT06054503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: prototype of sensor
Description: The investigational device is composed of a sensor placed on the respiratory line of the ventilated patients and connected to a ventilation measure unit which records the ventilation parameters
Study: NCT04913441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Patients in this group will get every session routine physical therapy of 30 minutes 3 times per week on alternative days for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual physical therapy with routine physical therapy
Description: Patients in this group will get every session Manual physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching physical therapy with routine physical therapy
Description: Patients in this group will get every session of Stretching physical therapy with routine physical therapy of 40 to 45 minutes 3 times per week on alternative days for 12 weeks
Study: NCT05144828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intercostal Nerve Cryoablation
Description: Patients will receive intraoperative intercostal nerve cryoablation using CryoICE® CRYOS-L cryoablation probes (AtriCure, Inc) to intercostal spaces 4th to 10th in thoracoabdominal aortic repairs and 4th to 8th in descending thoracic aortic repair cases prior to wound closure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Description: Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Description: Patients will have access to the standard PCA (patient-controlled analgesia) offered at Froedtert Hospital. This includes tylenol 650 mg oral, robaxin 500 mg oral, and tramadol 25-50 mg oral. All patients will have the first two ports placed at which time an intercostal nerve block of nerves 4-9 will be performed using 0.5% Marcaine with Epinephrine.
Study: NCT06007417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci004
Description: GenSci004 is a pegylated rhGH (PEG rhGH) (i.e., PEG-somatropin)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: Genotropin
Study: NCT05827289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Patients Better Life Experience (CAPABLE)
Description: The CAPABLE system serves three main goals for the patient: symptom monitoring, information needs fulfilment and interventions to improve mental- and physical wellbeing. These are available to the patient as a smartphone application that is connected to a smartwatch to monitor activity, blood pressure, sleep and heart rate. Patients are able to report symptoms experienced from the treatment and are eligible to do interventions such as mindfulness or yoga. Patients will receive the CAPABLE application and smartwatch for a minimum 3 to a maximum of 6 months after start treatment.
Study: NCT05719662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight bearing exercises
Description: Weight bearing exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jaffrey's core stability exercises
Description: Jaffrey's core stability exercises
Study: NCT05893576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Receive a single dose of HRS9531 of original formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9531
Description: Receive a single dose of HRS9531 of new formulation.
Study: NCT05947045

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training via iPad
Description: Participants will complete five sessions of the Cogmed training program on an iPad. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training via virtual reality
Description: Participants will complete five sessions of the Cogmed training program within virtual reality. Participants will complete sessions over the course of one to two weeks while on campus for radiotherapy. Each session will take place in the Psychology Clinic and consist of 15 to 20 minutes of Cogmed training.
Study: NCT05193370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Angiotensin II (Giapreza) is a pharmacologic version of a naturally occurring hormone of the same name, peptide hormone of the renin-angiotensin-aldosterone system (RAAS), that was FDA-approved in 2017 as a vasoconstrictive agent in the treatment of vasodilatory shock.
Study: NCT05162638

Intervention type: PROCEDURE
Group type: OTHER
Intervention: thoracic duct cannulation
Description: Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: thoracic duct cannulation
Description: Contrast is injected into lymph nodes until lymphatics visualized at about level of L3 lumbar spine. After target lymphatic vessel is identified, needle is passed transabdominally into the vessel. Guidewire is advanced through the needle into the lymph vessel \& advanced into thoracic duct. Microcatheter is then advanced into thoracic duct over the wire.~IN \& OUT-up to 100mL collected via catheter over 30-min at 2 levels within thoracic duct, then catheter removed.~INDWELLING-As described above, then guidewire placed through original catheter \& advanced into subclavian vein. Vascular sheath is placed into vein in the upper arm under ultrasound/fluoroscopy guidance. Wire in the subclavian vein then snared through venous access sheath \& pulled out. Catheter then threaded \& advanced over the wire until tip is in thoracic duct. Catheter from thoracic duct removed, leaving catheter extending from arm into thoracic duct. Catheter left in place up to 21 days for sampling.
Study: NCT05842525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive treatment
Description: Fruquintinib 4mg, orally, once daily, 3 weeks on/ 1 week off Irinotecan 150 mg/m2 LV 400 mg/m2 5-fluorouracil 400mg/m2 and a 46-48h continuous infusion 2400mg/m2 on day 1, q2w （intensive treatment up to 8 cycels）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance treatment
Description: Fruquintinib 5mg, orally, once daily, 3 weeks on/ 1 week off
Study: NCT06059677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active smoked cannabis
Description: Assessment of active cannabis smoking and driving impairment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo smoked cannabis
Description: Assessment of placebo cannabis smoking and driving impairment
Study: NCT05193370

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: Vasopressin (Vasostrict) is a pharmacologic version of a naturally occurring peptide hormone that serves as a vasoconstrictive agent in the treatment of vasodilatory shock.
Study: NCT04493957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCOMPAGNE Education Program
Description: The following workshops will be organised :~* Presentation workshop~* Cognitive skills workshop~* Perception and Environment workshop~* Responsibilities workshop~* Representation workshop -~* Caregivers workshop,~* Solutions workshop

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usuals recommandations
Description: Recommendations consist of a description of the cognitive and sensorimotor risk factors specific to the patient for driving and advice for the adaptation of driving or the recommendation of the stopping of driving. It is usually served by oral or written to the patient, with mention in the patient's file of the recommendation and issued in the presence of his close companion.
Study: NCT05646654

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 20 ml bupivacaine 0.5% will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: Using a lateral-to-medial approach, the 25-gauge needle will be inserted into the middle scalene muscle, advanced, and placed immediately lateral to the nerve roots. the needle will be visualize using an ultrasound beam to avoid intraneural and intravascular injections. After confirming negative blood aspiration, we will inject 15 mL of 0.5% bupivacaine around the nerve roots
Study: NCT06525038

Intervention type: OTHER
Intervention: All groups were observed for clinical end-points described in the study protocol
Description: All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.
Study: NCT04968964

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiviTum® TKa assay
Description: -Determines serum enzymatic activity of TK1

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiviTum® TKa assay
Description: -Determines serum enzymatic activity of TK1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Care Plans
Description: -Study Care Plans will be completed prior to and post release of serum DiviTum® TKa value
Study: NCT06068296

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: short term memory assessment
Description: Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: short term memory assessment
Description: Aphasia group: The Dutch verbal STM assessment tool will be administered over a time span of maximum two consecutive days depending on how fatigued the patient is during testing.~Healthy control group: the Dutch verbal STM assessment tool will be administered.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Oxford cognitive screen
Description: Evaluation of the cognitive abilities of the patients with aphasia.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Token Test
Description: Evaluation of the severity of the aphasia in patients with aphasia.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Montreal cognitive assessment
Description: Evaluation of cognitive dysfunction in the group of healthy volunteers.
Study: NCT05563714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinician Notification with Nurse Facilitation (CNNF)
Description: An anticoagulation clinic nurse sends a templated message to the patient's target clinician that identifies the patient as high risk for upper GI bleeding, summarizes guidelines on appropriate antiplatelet medication use and PPI gastroprotection, and recommends that the clinician consider either discontinuing the patient's antiplatelet medication(s) or initiating a PPI for gastroprotection. The nurse will also offer to pend the order for a PPI if the clinician wants to initiate a PPI and will provide education to the patient on any medication changes recommended by the clinician.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait list control
Description: The anticoagulation clinic will not send the clinician notification letter or other project-specific materials to the clinician or patient, and the patient will be included on a list of patients who will receive the intervention at the conclusion of the trial.
Study: NCT05016791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch-based heart rhythm monitoring
Description: For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~1. Routinely once per day from the day of randomisation till the 12-month visit after AF CA (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~2. If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~3. If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW.
Study: NCT05227300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onset Sodium Bicarbonate Inj., 8.4%, USP Neutralizing Additive Solution
Description: Onpharma's Onset sodium bicarbonate buffer to be added to a standard cartridge of dental local anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: Septodont's standard formulation of 2% lidocaine with epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Description: Septodont's standard formulation of 2% lidocaine with epinephrine
Study: NCT06284577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multistrain Probiotic
Description: Participants will recieve a multi-strain probiotic daily for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Placebo - maltodextrin
Description: Participants will recieve placebo/ maltodextri daily for 6 months
Study: NCT06111274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib (ABSK021)
Description: The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimicotinib (ABSK021)
Description: The ABSK021 will be taken orally, once daily; The Gemcitabine and nab-Pacilitaxel will be administrated with intravenous infusion on day 1 and 8 of each cycle; The Toripalimab will be administrated with intravenous infusion on day 1 of each cycle.
Study: NCT05755152

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polyphenol-lecithin precipitate (PLP)
Description: Chewing gum made with material produced from patented technology to rapidly isolate polyphenols from fruit juice (PLP).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control formulation
Description: Chewing gum made with material produced from conventional technology (e.g cranberry extract).
Study: NCT05469217

Intervention type: OTHER
Intervention: fMRI brain imaging
Description: Structural MRI of gray and white matter, functional MRI during performance of the N-back task

Intervention type: OTHER
Intervention: fMRI brain imaging
Description: Structural MRI of gray and white matter, functional MRI during performance of the N-back task
Study: NCT01795274

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Carbon Ion Radiotherapy
Description: Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
Study: NCT06295328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine
Description: terbinafine 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 250mg once daily for 4 weeks, followed by 2 weeks washout, followed by 4 weeks bid.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 245mg standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: Tenofovir 245mg standard of care
Study: NCT06525038

Intervention type: OTHER
Intervention: All groups were observed for clinical end-points described in the study protocol
Description: All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.

Intervention type: OTHER
Intervention: All groups were observed for clinical end-points described in the study protocol
Description: All groups were observed for clinical end-points (mortality, readmission to emergency service) described in the study protocol.
Study: NCT04787874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Program
Description: Nutrition component: Participants will receive information on how to follow a healthy diet (Mediterranean-style diet) with emphasis on whole foods, plants, lean protein, olive oil; restriction of red meats, processed meats, processed foods, added sugar)~Exercise component: Participants will receive an activity tracker to use during the study period (3+ weeks before surgery, and 30 days after surgery). Participants will be assigned strength exercises to work on core strength and proximal muscle strength (biceps/triceps, quads, hamstrings, calves).The exercises will mainly be focused on strengthening the abdominal wall. Exercises will be tailored to patients' individual capabilities. They will also be assigned cardio exercises - either low-intensity steady state cardio vs High Intensity Interval training. Level of cardio exercise will be tailored based on patient's Duke Activity score and baseline activity.
Study: NCT05559775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib Pill
Description: 13.5mg, po, 2 weeks on/1 week off, Q3W
Study: NCT03664648

Intervention type: BIOLOGICAL
Intervention: HEPLISAV-B
Description: This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
Study: NCT05233930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKR with augmented reality-based navigation system
Description: Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR with traditional mechanically aligned technique
Description: As per local practice and standard guidelines.
Study: NCT05217706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: The treatment group will receive Ketamine 0.2mg/kg IV once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: The placebo group will receive normal saline IV in a matched syringe
Study: NCT06024200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical acupoint stimulation
Description: Electrical stimulation is performed within 24h before surgery, 30min before anesthesia induction and 3 days after surgery, each stimulation was 30min. Patients are treated bilaterally at two groups of distal acupoints: one group consisted of Hegu (LI4) and Neiguan (PC6), the other contained Zusanli (ST36) and Shanyinjiao (SP6). Stimulation is delivered with adisperse-dense wave, 2Hz in frequency. The stimulation intensity is adjusted in accordance with the maximal level tolerated by each patient.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: transcutaneous electrical acupoint stimulation sham stimulation
Description: Patients are treated bilaterally at four sham acupoints of LI4, PC6, ST36 and SP6. These four pseudo-acupoints were located 1 cun ulnarlateral, and 7 cun and 9 cun proximal to Shenmen (HT7) ;and 9 cun and 12 cun proximal of Kunlun (BL60). These sham points are picked because there are no meridians or channels through these four sites. The stimulation intensity is adjusted in the lowest level felt by each patient. Other intervention details are similar to those of the experimental group.